Literature DB >> 24276616

Investigating the hydrogen-bond acceptor site of the nicotinic pharmacophore model: a computational and experimental study using epibatidine-related molecular probes.

Clelia Dallanoce1, Giovanni Grazioso, Diego Yuri Pomè, Miriam Sciaccaluga, Carlo Matera, Cecilia Gotti, Sergio Fucile, Marco De Amici.   

Abstract

The binding mode of nicotinic agonists has been thoroughly investigated in the last decades. It is now accepted that the charged amino group is bound by a cation-π interaction to a conserved tryptophan residue, and that the aromatic moiety is projected into a hydrophobic pocket deeply located inside the binding cleft. A hydrogen bond donor/acceptor, maybe a water molecule solvating this receptor subsite, contributes to further stabilize the nicotinic ligands. The position of this water molecule has been established by several X-ray structures of the acetylcholine-binding protein. In this study, we computationally analyzed the role of this water molecule as a putative hydrogen bond donor/acceptor moiety in the agonist binding site of the three most relevant heteromeric (α4β2, α3β4) and homomeric (α7) neuronal nicotinic acetylcholine receptor (nAChR) subtypes. Our theoretical investigation made use of epibatidine 1 and deschloroepibatidine 2 as molecular probes, and was then extended to their analogues 3 and 4, which were subsequently synthesized and tested at the three target receptor subtypes. Although the pharmacological data for the new ligands 3 and 4 indicated a reduction of the affinity at the studied nAChRs with respect to reference agonists, a variation of the selectivity profile was clearly evidenced.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24276616     DOI: 10.1007/s10822-013-9694-y

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  36 in total

1.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

2.  Design of novel alpha7-subtype-preferring nicotinic acetylcholine receptor agonists: application of docking and MM-PBSA computational approaches, synthetic and pharmacological studies.

Authors:  Giovanni Grazioso; Diego Yuri Pomè; Carlo Matera; Fabio Frigerio; Luca Pucci; Cecilia Gotti; Clelia Dallanoce; Marco De Amici
Journal:  Bioorg Med Chem Lett       Date:  2009-09-24       Impact factor: 2.823

3.  A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

Authors:  J P Sullivan; D Donnelly-Roberts; C A Briggs; D J Anderson; M Gopalakrishnan; M Piattoni-Kaplan; J E Campbell; D G McKenna; E Molinari; A M Hettinger; D S Garvey; J T Wasicak; M W Holladay; M Williams; S P Arneric
Journal:  Neuropharmacology       Date:  1996-06       Impact factor: 5.250

4.  Binding interactions with the complementary subunit of nicotinic receptors.

Authors:  Angela P Blum; Ethan B Van Arnam; Laurel A German; Henry A Lester; Dennis A Dougherty
Journal:  J Biol Chem       Date:  2013-01-24       Impact factor: 5.157

5.  Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2'-substituted 5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues.

Authors:  F I Carroll; F Liang; H A Navarro; L E Brieaddy; P Abraham; M I Damaj; B R Martin
Journal:  J Med Chem       Date:  2001-06-21       Impact factor: 7.446

6.  Nicotine-modulated subunit stoichiometry affects stability and trafficking of α3β4 nicotinic receptor.

Authors:  Francesca Mazzo; Francesco Pistillo; Giovanni Grazioso; Francesco Clementi; Nica Borgese; Cecilia Gotti; Sara Francesca Colombo
Journal:  J Neurosci       Date:  2013-07-24       Impact factor: 6.167

Review 7.  Neuronal nicotinic receptors in the human brain.

Authors:  D Paterson; A Nordberg
Journal:  Prog Neurobiol       Date:  2000-05       Impact factor: 11.685

Review 8.  Neuronal nicotinic receptors: from structure to pathology.

Authors:  C Gotti; F Clementi
Journal:  Prog Neurobiol       Date:  2004-12       Impact factor: 11.685

9.  Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease.

Authors:  Madhavi N L Nalam; Anik Peeters; Tim H M Jonckers; Inge Dierynck; Celia A Schiffer
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

10.  Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity.

Authors:  M J Parker; A Beck; C W Luetje
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

View more
  4 in total

1.  Novel 5-(quinuclidin-3-ylmethyl)-1,2,4-oxadiazoles to investigate the activation of the α7 nicotinic acetylcholine receptor subtype: Synthesis and electrophysiological evaluation.

Authors:  Marta Quadri; Almin Silnović; Carlo Matera; Nicole A Horenstein; Clare Stokes; Marco De Amici; Roger L Papke; Clelia Dallanoce
Journal:  Eur J Med Chem       Date:  2018-10-11       Impact factor: 6.514

2.  Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation.

Authors:  Maria Chiara Pismataro; Nicole A Horenstein; Clare Stokes; Marta Quadri; Marco De Amici; Roger L Papke; Clelia Dallanoce
Journal:  Eur J Med Chem       Date:  2020-07-28       Impact factor: 6.514

Review 3.  In Silico Modeling of the α7 Nicotinic Acetylcholine Receptor: New Pharmacological Challenges Associated with Multiple Modes of Signaling.

Authors:  Alican Gulsevin; Roger L Papke; Nicole Horenstein
Journal:  Mini Rev Med Chem       Date:  2020       Impact factor: 3.862

4.  Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity.

Authors:  L Legnani; D Colombo; A Venuti; C Pastori; L Lopalco; L Toma; M Mori; G Grazioso; S Villa
Journal:  Medchemcomm       Date:  2016-12-16       Impact factor: 3.597

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.